U.S. mass tort: Zantac (ranitidine) liti… | DrugsMonitor.com

Zantac (ranitidine) litigation: educational case snapshot only; individualized legal advice requires consulting a qualified attorney—not legal advice.

NDMA, ranitidine, recalled heartburn medication, cancer allegations

Ranitidine (Zantac) litigation alleged that the molecule could form N-nitrosodimethylamine (NDMA) under certain conditions and that long-term use increased cancer risk. Regulatory agencies pulled many ranitidine products from the market in 2020.

Procedural history

MDL No. 2924 centralized federal Zantac product liability cases. Daubert and preemption rulings significantly narrowed or ended many federal claims.

A small number of state-court paths may exist for limited scenarios; individualized legal research is required.

FAQ

Zantac / Ranitidine 诉讼是关于什么的?

此页面总结了 Zantac(雷尼替丁)诉讼 的公开诉讼背景和安全背景。它是教育性的——不是对您个人的案例评估。

此页面是法律建议吗?

不是。DrugsMonitor.com 不是律师事务所。此处没有任何内容告诉您是否拥有索赔权或您应该采取什么法律行动。

如何申请保密审查?

使用此页面上的信息收集或「申请保密审查」选项。只有在您选择继续时,才可能将您转介至合作伙伴律所。